A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder

Soltani, Farhad; Sayyah, Mehdi; Feizy, Fariba; Malayeri, Alireza; Siahpoosh, Amir; Motlagh, Ismail

doi:10.1002/hup.1145

Cited by 70 publications

(52 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The findings of small randomised placebocontrolled augmentation studies with 5-HT 3 antagonists provide evidence for the efficacy of the addition of ondansetron to fluoxetine [I (PCT)] (Soltani et al, 2010) and for the addition of granisetron to fluvoxamine [I (PCT)] (Askari et al, 2012). Three relatively small randomised placebo-controlled anticonvulsant augmentation studies indicate that the addition of topiramate to SSRIs reduces the severity of compulsions [I (PCT)] (Berlin et al, 2011), and of obsessive-compulsive symptoms [I (PCT)] (Mowla et al, 2010); and the addition of lamotrigine to SSRIs reduces the severity of obsessive-compulsive and affective symptoms [I (PCT)] (Bruno et al, 2012).…”

Section: Further Management After Nonresponse To Initial Treatmentmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Section: Further Management After Nonresponse To Initial Treatmentmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The other strategy is augmenting an SSRI with a serotonin 5-HT 3 receptor antagonist [77]. One double-blind RCT has shown the benefits of augmenting an SSRI with granisetron in adult OCD [78], and two doubleblind RCTs have shown the benefits of ondansetron in adult OCD [79,80]. These treatments are clearly to be used by experts in true treatment-refractory OCD.…”

Section: Other Possible Medicationsmentioning

confidence: 99%

Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder

Skarphéðinsson

Ivarsson

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Pediatric obsessive-compulsive disorder (OCD) is a chronic, disabling, and common disorder. In this paper, we describe evidence-based treatments in treatment-naïve and treatment-refractory pediatric OCD patients. We conducted a PubMed search to identify randomized controlled trials, reviews, and expert guidelines. The evidence for cognitive behavior therapy (CBT) and specific serotonin reuptake inhibitors (SSRIs) among treatment-naïve patients is substantial and shows that both treatments are effective. Head-to-head trials in pediatric OCD only show that CBT is significantly more effective than SSRI. The evidence among CBT and SSRI non-responders is limited. One trial among CBT non-responders showed that both continued CBT and switching to an SSRI are effective strategies. Likewise, one trial among SSRI non-responders showed that augmenting with CBT is necessary. Evidence of treatments for treatment-refractory pediatric OCD is lacking. We describe the treatments available and evidence from studies of adult OCD. Evidence for emerging treatments such as modifying CBT and glutamatergic drugs is also described.

show abstract

“…Augmentation of SSRIs with antipsychotic medication is the most evidence-based option, and a number of randomised double-blind placebo-controlled augmentation studies has shown that the addition of antipsychotic agents such as aripiprazole, haloperidol, olanzapine, quetiapine, or risperidone is effective in treatment-resistant OCD patients [18••]. The use of other medications such as ondansetron [19] and granisetron in combination with SSRIs [20] may also be effective. In addition, three relatively small randomised placebo-controlled anticonvulsant augmentation studies demonstrated that the addition of topiramate [21,22] or lamotrigine [23] to SSRIs reduced OCD severity.…”

Section: Ocdmentioning

confidence: 99%

Treatment of Obsessive-Compulsive and Related Disorders

Löchner

Stein²

2014

Curr Treat Options Psych

View full text Add to dashboard Cite

Pharmacotherapy and cognitive-behavioural therapy (CBT) have been studied in many of the obsessive-compulsive and related disorders (OCRDs). Serotonin reuptake inhibitors (SRIs) and cognitive-behavioural therapies (CBT) are first-line considerations in many, but not all, of these conditions. There are fewer data available on the combination of these treatment modalities in OCRDs. In obsessive-compulsive disorder (OCD), the SRIs and CBT -which include exposure and response prevention (ERP) -are wellestablished safe and efficacious first-line treatments in adult and paediatric populations. While various pharmacotherapy augmentation strategies have been studied, the most evidence-based approach to date is augmentation with antipsychotic agents. There is also evidence of the value of CBT in the management of treatment-refractory patients. A number of SRIs, such as clomipramine and fluoxetine, have shown efficacy in randomized controlled trials of the pharmacotherapy of body dysmorphic disorder (BDD). There are relatively few data on pharmacotherapy augmentation approaches in BDD. CBT has also been found efficacious in a number of psychotherapy trials of BDD. Less is known about the optimal treatment of the other OCRDs, i.e., hoarding disorder (HD), trichotillomania (hair-pulling disorder, or HPD), and excoriation (skin-picking) disorder (SPD). While patients with HD may have been included in RCTs on OCD, no data from randomized controlled trials of pharmacotherapy specifically for HD have been reported. There is some support for the value of CBT in HD. In HPD, controlled trials of olanzapine, N-acetyl cysteine (NAC), and clomipramine (vs. desipramine) have provided evidence of efficacy. There also is evidence supporting the efficacy of behaviour therapy in reducing hair-pulling. Results from randomized controlled trials of SRIs in SPD have been mixed, with some agents such as fluoxetine and citalopram demonstrating improvement on certain measures of picking behaviour. Behaviour therapy also appears to be useful for SPD.

show abstract

A double‐blind, placebo‐controlled pilot study of ondansetron for patients with obsessive‐compulsive disorder

Abstract: The results of this study show that ondansetron has positive effects on obsession and compulsion which start two weeks after the beginning of the treatment.

Cited by 70 publications

References 20 publications

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder

Treatment of Obsessive-Compulsive and Related Disorders

Contact Info

Product

Resources

About